Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
A new study reveals that daily use of eye drops, which combine pilocarpine and diclofenac, can significantly enhance near vision for presbyopia patients.
The University of Oxford has launched a £118M AI vaccine research programme, CoI-AI, with the Ellison Institute, aiming to combat antibiotic resistance through human challenge trials.
UCSF researchers report a new spatial repellent that provides up to one year of protection against malaria and other mosquito-borne diseases, marking the first WHO-endorsed vector control tool in over four decades.
Murdoch Children’s Research Institute launches an international trial of a 21-valent pneumococcal vaccine to protect babies against pneumonia, meningitis, and sepsis.
NICE has endorsed idebenone (Raxone) on the NHS to treat Leber’s hereditary optic neuropathy in individuals aged 12 and over, offering hope to around 250 people.
Stanford researchers have developed an AI-powered "virtual scientist" capable of designing drug and vaccine candidates, marking a leap forward in biomedical research.
A breakthrough treatment for severe hay fever caused by birch pollen will soon be available on the NHS, as NICE recommends the first daily immunotherapy tablet for patients who don’t respond to standard therapies.
The UK has approved its first-ever needle-free adrenaline treatment for severe allergic reactions, marking a major development in how anaphylaxis could be managed in emergencies.
The NHS will offer a long-acting antibody injection to protect thousands of premature and vulnerable babies from respiratory syncytial virus (RSV) starting this autumn.
